G51 Stock Overview An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Genscript Biotech Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Genscript Biotech Historical stock prices Current Share Price HK$1.18 52 Week High HK$2.24 52 Week Low HK$0.96 Beta 1.08 1 Month Change -7.81% 3 Month Change -13.24% 1 Year Change -46.12% 3 Year Change -69.43% 5 Year Change -42.72% Change since IPO 755.07%
Recent News & Updates
Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group Nov 13
New major risk - Share price stability Oct 02
Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma Sep 29
Genscript Biotech Corporation Announces Board Appointments Sep 12
First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023) Sep 01
First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023) Aug 11 See more updates
Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group Nov 13
New major risk - Share price stability Oct 02
Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma Sep 29
Genscript Biotech Corporation Announces Board Appointments Sep 12
First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023) Sep 01
First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023) Aug 11
Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024 Jul 30
Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees Jun 24
GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market Jun 19
Now 22% undervalued after recent price drop May 21
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications May 14
Now 22% undervalued after recent price drop May 03
Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022) Apr 24
Now 22% undervalued after recent price drop Apr 16
Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee Apr 12
New major risk - Share price stability Mar 23
Genscript Biotech Corporation, Annual General Meeting, May 17, 2024 Mar 12
Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022) Mar 11
Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board Mar 09
Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024 Feb 28
New minor risk - Profitability Feb 28
New minor risk - Share price stability Nov 14
GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services Sep 19
First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022) Aug 22 Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023 Aug 10
Insider recently sold €159k worth of stock Apr 25
Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021) Apr 02
Genscript Biotech Corporation Announces Chief Executive Officer Changes Dec 20
Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022 Dec 19
Now 20% undervalued Dec 17
Less than half of directors are independent Nov 16
First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021) Sep 01
Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022 Aug 20
Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022 Aug 08
Genscript Biotech Corporation Announces Board Changes Aug 06
Genscript Biotech Corporation Announces Board Changes May 04
Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020) Apr 27
Less than half of directors are independent Apr 27
Genscript Biotech Corporation, Annual General Meeting, May 27, 2022 Mar 23
Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021 Feb 19
Board Member recently sold €246k worth of stock Dec 01
First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020) Sep 24
First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020) Aug 25
Key Executive recently sold €988k worth of stock Jul 24
Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test Jun 22
Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation. Jun 12
Genscript Biotech Corporation and Legend Biotech Corporation Announce New and Updated Results for Ciltacabtagene Autoleucel (cilta-cel), an Investigational BCMA-Directed CAR-T Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma to be Featured at the 2021 ASCO Annual Meeting and at the EHA Virtual Congress May 29
Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019) Apr 17
Full year 2020 earnings released Mar 27
Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021 Mar 12
New 90-day high: €1.40 Feb 23
Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology Feb 20
New 90-day low: €1.06 Jan 16
New 90-day low: €1.08 Nov 24
Genscript Biotech Corporation Announces Board and Director Changes Nov 24
New 90-day low: €1.25 Oct 24
Co-Founder recently bought €410k worth of stock Sep 29
First half earnings released Sep 24
New 90-day low: €1.28 Sep 23
First half earnings released Sep 01
New 90-day low - €1.60 Aug 28
Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020 Aug 22
New 90-day low - €1.66 Aug 12
Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020 Aug 03 Shareholder Returns G51 DE Life Sciences DE Market 7D -4.1% -2.8% -2.6% 1Y -46.1% -5.9% 6.9%
See full shareholder returns
Return vs Market: G51 underperformed the German Market which returned 7.1% over the past year.
Price Volatility Is G51's price volatile compared to industry and market? G51 volatility G51 Average Weekly Movement 9.3% Life Sciences Industry Average Movement 7.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: G51's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: G51's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including DNA synthesis, plasmid DNA preparation, molecular cloning, oligonucleotide synthesis, protein and antibody expression and purification, peptide synthesis, antibody development, IVT RNA production, assay cell line development and vector packing, molecular diagnostics tools, and genome editing tools and reagents, as well as instrument for protein analysis and purification, cell isolation and activation.
Show more Genscript Biotech Corporation Fundamentals Summary How do Genscript Biotech's earnings and revenue compare to its market cap? G51 fundamental statistics Market cap €2.57b Earnings (TTM ) -€169.65m Revenue (TTM ) €967.59m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) G51 income statement (TTM ) Revenue US$1.01b Cost of Revenue US$468.10m Gross Profit US$541.49m Other Expenses US$718.50m Earnings -US$177.01m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.083 Gross Margin 53.63% Net Profit Margin -17.53% Debt/Equity Ratio 48.1%
How did G51 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 13:43 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Genscript Biotech Corporation is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Linda Lu BOCI Research Ltd. Jin Zhang China International Capital Corporation Limited Yue-Kwong Lui China Renaissance Securities
Show 18 more analysts 
